Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor.

Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E.

PLoS One. 2010 Feb 5;5(2):e9060. doi: 10.1371/journal.pone.0009060.

2.

Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.

Tran C, Richmond O, Aaron L, Powell JB.

Biochem Pharmacol. 2013 Mar 15;85(6):753-62. doi: 10.1016/j.bcp.2012.12.010. Epub 2012 Dec 22.

3.

Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity.

Kollara A, Brown TJ.

J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):51-8. doi: 10.1016/j.jsbmb.2009.09.017. Epub 2009 Oct 6.

PMID:
19815066
4.

The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells.

Richmond O, Ghotbaddini M, Allen C, Walker A, Zahir S, Powell JB.

PLoS One. 2014 Apr 22;9(4):e95058. doi: 10.1371/journal.pone.0095058. eCollection 2014.

5.
6.

Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.

Morrow D, Qin C, Smith R 3rd, Safe S.

J Steroid Biochem Mol Biol. 2004 Jan;88(1):27-36.

PMID:
15026081
7.

Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer.

Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, Mukai M, Okada Y, Oya M.

Carcinogenesis. 2010 Feb;31(2):287-95. doi: 10.1093/carcin/bgp222. Epub 2009 Sep 15.

PMID:
19755661
9.

TGF-β1 signaling plays a dominant role in the crosstalk between TGF-β1 and the aryl hydrocarbon receptor ligand in prostate epithelial cells.

Staršíchová A, Hrubá E, Slabáková E, Pernicová Z, Procházková J, Pěnčíková K, Seda V, Kabátková M, Vondráček J, Kozubík A, Machala M, Souček K.

Cell Signal. 2012 Aug;24(8):1665-76. doi: 10.1016/j.cellsig.2012.04.008. Epub 2012 Apr 25.

PMID:
22560882
10.

Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells.

Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB.

Cancer Res. 2004 Apr 1;64(7):2523-33.

11.

The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells.

Ghotbaddini M, Powell JB.

Int J Environ Res Public Health. 2015 Jul 6;12(7):7506-18. doi: 10.3390/ijerph120707506.

12.
13.

Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands.

Hrubá E, Vondráček J, Líbalová H, Topinka J, Bryja V, Souček K, Machala M.

Toxicol Lett. 2011 Oct 10;206(2):178-88. doi: 10.1016/j.toxlet.2011.07.011. Epub 2011 Jul 23.

PMID:
21802500
14.

Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells.

Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):462-8.

PMID:
10080920
15.

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J.

Cancer Res. 2013 Jun 15;73(12):3725-36. doi: 10.1158/0008-5472.CAN-12-3468. Epub 2013 Mar 28.

16.
19.

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ.

Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107.

20.

Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer.

Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, Minamoto T.

J Natl Cancer Inst. 2004 Aug 4;96(15):1161-70.

PMID:
15292388

Supplemental Content

Support Center